547 related articles for article (PubMed ID: 20525923)
21. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
22. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
23. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
[TBL] [Abstract][Full Text] [Related]
24. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
26. Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.
Godbersen JC; Paiva C; Danilova OV; Berger A; Brown JR; Danilov AV
Leuk Lymphoma; 2015 May; 56(5):1566-9. PubMed ID: 26086969
[TBL] [Abstract][Full Text] [Related]
27. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
28. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
29. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
30. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
Yang D; Tan M; Wang G; Sun Y
PLoS One; 2012; 7(3):e34079. PubMed ID: 22457814
[TBL] [Abstract][Full Text] [Related]
31. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.
Milhollen MA; Narayanan U; Soucy TA; Veiby PO; Smith PG; Amidon B
Cancer Res; 2011 Apr; 71(8):3042-51. PubMed ID: 21487042
[TBL] [Abstract][Full Text] [Related]
33. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
[TBL] [Abstract][Full Text] [Related]
34. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
35. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
36. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
37. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
[TBL] [Abstract][Full Text] [Related]
38. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
39. Neddylation inhibition activates the protective autophagy through NF-κB-catalase-ATF3 Axis in human esophageal cancer cells.
Liang Y; Jiang Y; Jin X; Chen P; Heng Y; Cai L; Zhang W; Li L; Jia L
Cell Commun Signal; 2020 May; 18(1):72. PubMed ID: 32398095
[TBL] [Abstract][Full Text] [Related]
40. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
